CYDY News Alert Cytodyn Inc (CYDY) 0.7900 09/27/2014 20:30:5

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytodyn Inc (CYDY) 0.7900 $CYDY

CytoDyn Announces Webcast for Annual Shareholder Meeting
GlobeNewswire - Fri Aug 15, 2:06PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that its August 20, 2014 annual meeting of shareholders will be shared live through a webcast that will allow the public to access the audio portion of the meeting, as well as management's presentation.

CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Thu Jul 31, 7:21AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced positive interim results from its Phase 2b treatment substitution study. The Company will hold an investment community conference call on August 4, 2014, at 9:00 a.m. PT to discuss the trial's protocol, clinical results, and anticipated path forward, as well as to address questions from the call's participants.

CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Wed Jul 30, 8:52PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Monday, August 4, 2014 at 9:00 a.m. PT to discuss the interim results from its ongoing Phase 2b treatment substitution study in patients with HIV.

OTC Market Trading List: CytoDyn, Inc. Alliance Semiconductor Corp, Bayside Corp, In Ovations Holdings, Novagant Corp.
PR Newswire Europe - Fri Jun 20, 7:52AM CDT
LONDON, June 20, 2014 /PRNewswire/ --

CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy
Business Wire - Wed Mar 19, 7:05AM CDT
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company will host a live conference call and webcast with the investment community on Tuesday, March 25, 2014 at 1:30 p.m. PT to provide an update on the Company's clinical development strategy for lead product candidate, PRO 140, including progress with its preparations for its treatment substitution Phase 2b study in patients with Human Immunodeficiency Virus (HIV). PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

CytoDyn Files Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV
Close-Up Media - Thu Feb 20, 11:36PM CST
CytoDyn Inc., a biotechnology company focusing on the development of new therapies for combating infection with immune deficiency viruses, said that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140
Business Wire - Tue Jan 28, 7:05AM CST
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company plans to expand its clinical development program for PRO 140 and signed an agreement with Amarex Clinical Research LLC to prepare two Phase 2b clinical trial protocols to explore two additional therapeutic indications for its lead product candidate. One of the new protocols is expected to be completed in the first quarter of 2014 and the second protocol early in the second quarter of 2014. After submission of the Phase 2b clinical trial protocols to the U.S. Food and Drug Administration (FDA), the Company and Amarex will work with the FDA to obtain approval to commence the trials.

OTC Daily Alert Stock Watch - CytoDyn (OTCQB: CYDY)
WorldStockWire - Thu Aug 15, 10:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

CytoDyn Inc names Anthony D. Caracciolo as board chair
M2 - Tue Jun 18, 6:13AM CDT
Biotechnology company CytoDyn Inc (OTC QB:CYDY) revealed on Monday the appointment of Anthony D. Caracciolo as chairman of the board of directors with immediate effect.

CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
Business Wire - Mon Jun 17, 3:52PM CDT
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that Anthony D. Caracciolo has been appointed Chairman of the Board of Directors effective June 17, 2013. Past Chairman, Gregory A. Gould, will remain a member of the Board of Directors and continue to serve as Chair of the Audit Committee.

CytoDyn Announces Important Milestone Achieved to Initiate Phase IIb Studies
Business Wire - Mon Apr 29, 3:11PM CDT
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for the treatment of human immunodeficiency virus (HIV) infection, announced that CytoDyn Inc. and Drexel University have entered into a contract with Ajinomoto Althea, Inc. to formulate CytoDyn's PRO 140 bulk drug substance through a "fill and finish" process resulting in clinical-ready vials to advance its two NIH-funded Phase IIb studies. These trials will be conducted by Drexel University and are funded by over $10 million in grants from the National Institute of Health (NIH). Ajinomoto Althea, Inc. is a contract development and manufacturing company based in San Diego, California.

CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
Business Wire - Wed Feb 27, 8:00AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology at the BIOCOM Global Life Sciences Partnering Conference at the Lodge in Torrey Pines, La Jolla, California.

CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection
Business Wire - Tue Feb 26, 10:29AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a research collaboration with Dr. Bruce Torbett of The Scripps Research Institute to study CytoDyn's experimental humanized anti-CCR5 antibody PRO 140 in a pre-exposure prophylaxis (PrEP) model of HIV infection.

CytoDyn Announces Investor Update Conference Call on Friday, February 22
Business Wire - Tue Feb 19, 8:00AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will conduct a shareholder update conference call at 10:00 AM PST on Friday, February 22, 2013.

CytoDyn to Attend 31st Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 07, 6:51AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology during the 31st Annual J.P. Morgan Healthcare Conference on January 9, 2013 at 3:15 PM PT. More information regarding the conference can be found at http://www.ebdgroup.com/bts/index.php.

CytoDyn Appoints Former Ambassador to Bahrain as Middle East Business Consultant
Business Wire - Wed Jan 02, 7:52AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it has entered into a consulting agreement with former U.S. Ambassador Sam Zakhem.

CytoDyn Elects Two New Directors and Appoints New Chief Financial Officer
Business Wire - Tue Dec 18, 8:17AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced the election of Michael Nobel, Ph.D., and Allan M. Green, M.D., Ph.D., J.D., to the company's Board of Directors at its annual shareholders meeting held on December 12, 2012. CytoDyn also announced the appointment of Michael D. Mulholland as the company's new Chief Financial Officer, Treasurer and Corporate Secretary, effective December 13, 2012.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 87

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 272

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 127

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 87

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 21

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 82

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 56

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 35

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 161

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Mark Uyeda Takes the Lead as Acting SEC Chair Under Trump

Updated Category News Views 131

Mark Uyeda Appointed Acting Chair of the SEC Recently inaugurated President Donald Trump has appointed Mark Uyeda, a Republican member of the U.S. Securities and Exchange Commission (SEC), as the acting chair of the agency. This announcement from the White House marks a significant moment in the leadership of one of the country’s key financial regulatory bodies....

Continue Reading
Diaper Bank Marks Historic Milestone: One Million Diapers Given

Updated Category News Views 146

Diaper Bank Celebrates a Significant Achievement The Diaper Bank of the Inland Empire has proudly reached a wonderful milestone by distributing its one millionth diaper to families in need. This accomplishment underscores the vital role of community support and the ongoing necessity for resources to help families tackle diaper shortages. Dedicated to Community Needs...

Continue Reading
Franklin Electric Boosts Dividend Amid Strong Business Outlook

Updated Category News Views 159

Franklin Electric Announces Increased Quarterly Cash Dividend Franklin Electric Co., Inc. (NASDAQ: FELE) has made headlines with its recent announcement regarding a quarterly cash dividend of $0.265 per share. This decision reflects the company's robust financial health and a solid commitment to delivering value to its shareholders. The upcoming payment, set for February...

Continue Reading
GLS Italy Partners with Quadient to Elevate Parcel Services

Updated Category News Views 461

GLS Italy Enhances Delivery Options with Quadient Partnership GLS is making significant strides in the field of e-commerce delivery innovation by expanding its network of pick-up points. This expansion comes in the wake of a strategic partnership with Quadient, a leader in automation technologies, which introduces smart, carrier-agnostic lockers into the Italian market....

Continue Reading
Understanding Baidu's Unusual Options Trends and Insights

Updated Category News Views 155

Analyzing Baidu's Options Activity Investors and analysts are taking a close look at the unusual options activity surrounding Baidu. Recent patterns suggest that major players in the market are positioning themselves with a bearish outlook, raising interest among traders. Particularly, the volume of activity in the options market for Baidu (NASDAQ: BIDU) signals a notable...

Continue Reading